AGC Biologics

Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Program data pending ClinicalTrials.gov matching · Last scored 2026-03-15
85.0
Signal Score
✓ FDA Inspections (1) ○ Clinical Trials ○ SEC Filings ✓ Press (6)

Quick Facts: AGC Biologics

Signal Score
85.0/100 (as of 2026-03-15)
Quality Compliance
100.0/100
Headquarters
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Modalities
CAR-T, Cell Therapy, AAV, Lentiviral
Active CGT Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CGT manufacturing intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance 100.0
FDA Inspections1 on record
Warning Letters0
Last InspectionVoluntary Action Indicated (VAI) (2025-04-18)
Operations 82.3
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Source: ClinicalTrials.gov
No clinical trial matches found for this manufacturer · Operational score requires ClinicalTrials.gov data
Programs no verified data
Sponsorsno verified data
ModalitiesCAR-T, Cell Therapy, AAV, Lentiviral
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 75.0
Strong parent backing: AGC Inc. (Japan)
Source: SEC EDGAR, press monitoring
Subsidiary of AGC Inc.
SEC FilingsParent: AGC Inc.
Strong parent backing: AGC Inc. (Japan)
Capacity 72.0
3 CGT manufacturing sites
Broad modality coverage (4 modalities)
Facility expansion news detected
Sites: Longmont, CO, Milan, Italy, Chiba, Japan
Source: SEC EDGAR, press monitoring, company profiles
3 CGT manufacturing sites
StatusAvailable
3 CGT manufacturing sites
Broad modality coverage (4 modalities)
Facility expansion news detected
Sites: Longmont, CO, Milan, Italy, Chiba, Japan
Recent Press6 articles
3 CGT manufacturing sites
Broad modality coverage (4 modalities)
Facility expansion news detected

FDA Inspection History

2025-04
NAI VAI OAI
Date Site Type Observations Classification
2025-04-18 Bothell, Washington Blood and Blood Products No Voluntary Action Indicated (VAI)
Source: FDA Data Dashboard · Retrieved Mar 20, 2026

Recent News 6 articles

facility_expansion 2026-03-10
AGC Biologics Expands Capacity at Berkeley, California Facility | Libero Quotidiano.it - Libero Quotidiano
AGC Biologics Expands Capacity at Berkeley, California Facility | Libero Quotidiano.it  Libero Quotidiano
general 2026-03-02
Continuous Manufacturing Market Trends and Global Forecasts, 2035 Featuring Key Players - AbbVie, Abzena, AGC Biologics, Boehringer Ingelheim, Corden Pharma, Glatt, Kaneka, Phlow, and Wuxi Biologics - Yahoo Finance UK
Continuous Manufacturing Market Trends and Global Forecasts, 2035 Featuring Key Players - AbbVie, Abzena, AGC Biologics, Boehringer Ingelheim, Corden Pharma, Glatt, Kaneka, Phlow, and Wuxi Biologics  Yahoo Finance UK
general 2026-03-02
Continuous Manufacturing Market Trends and Global Forecasts, 2035 Featuring Key Players - AbbVie, Abzena, AGC Biologics, Boehringer Ingelheim, Corden Pharma, Glatt, Kaneka, Phlow, and Wuxi Biologics - Yahoo Finance
Continuous Manufacturing Market Trends and Global Forecasts, 2035 Featuring Key Players - AbbVie, Abzena, AGC Biologics, Boehringer Ingelheim, Corden Pharma, Glatt, Kaneka, Phlow, and Wuxi Biologics  Yahoo Finance
general 2026-02-03
AGC Biologics Seattle Site Now Certified to Manufacture Biologics for Largest Pharmaceutical Market in South America - The Joplin Globe
AGC Biologics Seattle Site Now Certified to Manufacture Biologics for Largest Pharmaceutical Market in South America  The Joplin Globe
general 2026-02-03
AGC Biologics Seattle Site Now Certified to Manufacture Biologics for Largest Pharmaceutical Market in South America - Business Wire
AGC Biologics Seattle Site Now Certified to Manufacture Biologics for Largest Pharmaceutical Market in South America  Business Wire
regulatory 2026-02-03
AGC Biologics Seattle Site Receives Anvisa GMP Certification - Contract Pharma
AGC Biologics Seattle Site Receives Anvisa GMP Certification  Contract Pharma
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
CAR-T CDMOs → Cell Therapy CDMOs → AAV CDMOs → Lentiviral CDMOs →